Key TakeawaysFutures declined Tuesday morning as crude oil neared $100 per barrel, intensifying speculation about Federal Reserve policy tighteningIntel topped premarket gainers in the S&P 500, with AMD and Marvell following suit amid sustained AI semiconductor enthusiasmNovartis plummeted 13% following failed clinical trial for muscle disorder treatment, triggering declines in Sarepta and Dyne TherapeuticsRoivant Sciences soared 20% on encouraging Phase 2 data from subsidiary’s lung disease therapy candidateASML gained 2% after major chipmakers validated commitment to adopting next-generation manufacturing equipmentEquity futures traded in negative territory Tuesday morning as Brent crude maintained levels above $98 per barrel. The escalating energy costs are amplifying market expectations for the Federal Reserve to implement additional rate increases during its upcoming policy meeting.However, semiconductor stocks focused on artificial intelligence applications defied the broader market weakness during early trading hours. Intel emerged as the S&P 500’s leading performer in premarket activity, advancing 3.6%. Advanced Micro Devices and Marvell experienced similar upward momentum, accompanied by gains in Micron and Sandisk.Semiconductor Sector Defies Market HeadwindsASML contributed to the optimistic semiconductor narrative, climbing 2% after verification that Samsung, Taiwan Semiconductor Manufacturing, and Intel are proceeding with implementation strategies for its High-NA extreme ultraviolet lithography systems.ASML Holding N.V., ASMLASML’s Chief Technology Officer indicated that a proposed transition from 6-inch to 12-inch photomasks has potential to enhance machine productivity by as much as 40%. TSMC and ASML are working toward establishing a 12-inch mask testing facility by 2031, followed by full-scale commercial manufacturing by 2033.Roivant Sciences captured the position of Tuesday’s strongest performer, skyrocketing 20%. Its subsidiary Pulmovant disclosed encouraging Phase 2 clinical data for mosliciguat, an experimental therapy targeting pulmonary hypertension associated with interstitial lung disease.The investigational treatment achieved its primary efficacy measure, demonstrating approximately 56% reduction in pulmonary vascular resistance versus placebo. Additional benefits included improving six-minute walking capacity by roughly 35 meters and reducing a critical cardiac stress biomarker by 53%.Pharmaceutical Stocks Retreat Following Novartis DisappointmentNovartis declined 13% after its late-phase clinical study evaluating muscle-wasting treatment del-desiran missed its primary efficacy target. This marked the pharmaceutical giant’s third consecutive clinical development failure within a single week.$NVS shares are falling as much as 10% after Novartis’ del-desiran failed the pivotal Phase 3 HARBOR study in myotonic dystrophy type 1, missing its primary endpoint on muscle function.It’s Novartis’ second major late-stage trial setback in a matter of days, following the… pic.twitter.com/xJhz2KwTRW— Wall St Engine (@wallstengine) September 8, 2026The clinical setback reverberated throughout the biotechnology sector. Dyne Therapeutics plunged 30%, Sarepta Therapeutics retreated 11%, and NewAmsterdam Pharma slipped 9%.Novartis’s troubles also pressured Amgen, which declined nearly 5%. Amgen is advancing its own cardiovascular therapeutic candidate called olpasiran, prompting investor concern about similar developmental risks.Novartis’s Chief Medical Officer characterized clinical setbacks as inherent components of pharmaceutical innovation. The organization maintained its projected 5% to 6% annual revenue expansion guidance extending through 2030.Zim Integrated Shipping Services advanced 6% following announcements from Hapag-Lloyd and private equity partner FIMI that they would modify their proposed $4.2 billion takeover after consultations with Israeli authorities.The transaction has encountered resistance within Israel from labor unions, defense establishment representatives, and government officials citing national security considerations. Hapag-Lloyd acknowledged ongoing collaboration with Israeli government stakeholders to implement structural adjustments to the acquisition framework.Fuel-cell manufacturer Bloom Energy rose 5.9%, data infrastructure company Everpure increased 3%, and biotechnology firm Illumina ticked up 0.9%. All three companies are scheduled for S&P 500 inclusion on September 21.Builders FirstSource, Molson Coors Beverage, and Trade Desk face removal from the S&P 500, and all three experienced declines on Tuesday.The post Market Shake-Up: Intel (INTC) Surges on AI Demand as Novartis Drug Failure Hammers Biotech Sector appeared first on Blockonomi.